MetLife (MET) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $2.43
- Estimate
- $2.29
- Surprise
- +6.2%
- Score today
- 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
MetLife (MET) beat the $2.29 estimate with diluted EPS of $2.43 — a clear 6.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MET Sell at 5.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +6.2% surprise compares with a +5.3% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Target reached (-4.7% upside)
- Quality below floor (3.4 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $99.23
- Price target
- $114.11
- Stop
- $95.39
- Upside to target
- +15.0%
The stock trades at 18.1× trailing but 8.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
MET at TrendMatrix's latest read
For financials, the EPS print is only half the story: credit costs, reserve builds, and rate sensitivity decide how a quarter actually lands.
- Industry
- Insurance - Life
- Market cap
- $61.27B
- P/E (fwd)
- 8.8
- P/E (ttm)
- 18.1
- 52-week range
- $67.33–$100.93
- Off 52-week high
- 1.7%
- RSI (14)
- 55
- Volume vs avg
- 1.29×
- Score today
- 5.1/10